A double-blinded, randomized, placebo-controlled, proof-of-concept trial in which patients with SSc-PAH received infusions of rituximab showed improvement in 6-min walk distance (6MWD) did not reach statistical significance ( 79 ).
← all excerpts
Clinical features of pulmonary arterial hypertension associated with systemic sclerosis.
1
—
—